Novartis CEO Circumspect About Biotech Bargains
As Renowned Analyst Ronny Gal Jumps Aboard
Executive Summary
Vas Narasimhan tells Scrip that a return to sensible valuations of biotechs could lead to increased deal-making but cautions that a number of those companies that went public "may not have been mature enough with their science” and their true value remains unclear.
You may also be interested in...
Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters
Novartis has led the sector in number of launches, but has failed to find a mega-blockbuster to lift its standing in the US – its CEO hopes new leaders can help turn that around.
Almirall Views Vitiligo As Next Dermatology Opportunity
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.
Boehringer Bids To Go Beyond Slowing IPF
The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.